908 Devices Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 908 Devices Inc. (Nasdaq: MASS) develops and commercializes purpose-built handheld chemical analysis devices leveraging mass spectrometry, microfluidic separations, and optical spectroscopy technologies for point-of-need detection and identification of hazardous substances in vital health, safety, and defense applications. The company offers MX908, a handheld mass spectrometer for trace-level analysis of solids, liquids, vapors, and aerosols including narcotics, explosives, precursors, and chemical threats; VipIR and XplorIR, portable analyzers combining FTIR and Raman spectroscopy with smart spectral processing for bulk solid/liquid identification and gas/vapor quantification at ppm levels; MX908 Beacon for enhanced area monitoring; and robotic-integrated gas detectors, serving customs and borders, hazmat/CBRN response, EOD, narcotics enforcement, and industrial monitoring markets. 908 Devices operates in the United States, Europe, the Middle East, Africa, Asia Pacific, and other regions. Founded in 2012 and headquartered at 645 Summer Street in Boston, Massachusetts, the company went public in 2020. In March 2025, Repligen Corporation acquired 908 Devices' bioprocessing analytics portfolio, including desktop devices Rebel, Maverick, Maven, and related accessories for real-time bioprocess monitoring of glucose, lactate, biomass, and media analysis, allowing 908 Devices to concentrate on handheld platforms for chemical detection; in 2024, it acquired RedWave Technology, integrating portable FTIR analyzers to expand forensics offerings and bolster optical capabilities for first responders.
Company News
Comparing 908 Devices (NASDAQ:MASS) & Plexus (NASDAQ:PLXS)
BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASS
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices Q2: Another Solid Report
908 Devices: Mission Critical Devices Drive Growth
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Q2 Earnings Call Highlights
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026